Enteroglucagon release in disaccharide malabsorption induced by intestinal alpha-glucosidase inhibition
- PMID: 2655436
Enteroglucagon release in disaccharide malabsorption induced by intestinal alpha-glucosidase inhibition
Abstract
To study the effects of acarbose, an alpha-glucosidase inhibitor, on saccharide absorption and pancreatic and gut hormone release, we loaded 50 g glucose (GTT), maltose (MTT), and sucrose (STT) to 12 healthy male volunteers with and without acarbose (0, 100, or 300 mg) in a double-blind protocol. Oral load of 300 mg acarbose did not inhibit absorption of 50 g glucose; neither did it alter subsequent responses of insulin and glucagons. Maltose absorption was not influenced by acarbose up to 300 mg. However, insulin response was reduced and eteroglucagon response was enhanced by acarbose. Acarbose 100 mg markedly decreased absorption of sucrose, resulting in inhibition of plasma elevation of glucose and insulin and in enhancement of enteroglucagon release. Oral load of 30 g lactulose, nonabsorbable disaccharide, could reproduce the acarbose-induced enteroglucagon release. An increase in osmotic pressure due to retention of unabsorbed carbohydrate in the distal small intestine and proximal colon may explain the acarbose-induced enteroglucagon release and diarrhea that results from STT with acarbose.
Similar articles
-
A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.Drug Saf. 1994 Dec;11(6):432-44. doi: 10.2165/00002018-199411060-00005. Drug Saf. 1994. PMID: 7727053 Review.
-
Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man.Dig Dis Sci. 1987 Feb;32(2):139-44. doi: 10.1007/BF01297101. Dig Dis Sci. 1987. PMID: 3542445 Clinical Trial.
-
Inhibition of disaccharide digestion in rat intestine by the alpha-glucosidase inhibitor acarbose (BAY g 5421).Digestion. 1982;23(4):232-8. doi: 10.1159/000198755. Digestion. 1982. PMID: 6754513
-
Long-term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics on sulphonylureas.Diabet Med. 1986 Mar;3(2):155-60. doi: 10.1111/j.1464-5491.1986.tb00728.x. Diabet Med. 1986. PMID: 2951158 Clinical Trial.
-
Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes.Eur J Clin Invest. 1994 Aug;24 Suppl 3:25-30. doi: 10.1111/j.1365-2362.1994.tb02252.x. Eur J Clin Invest. 1994. PMID: 8001623 Review.
Cited by
-
Inhibitory effect and mechanism of acarbose combined with gymnemic acid on maltose absorption in rat intestine.World J Gastroenterol. 2001 Feb;7(1):9-15. doi: 10.3748/wjg.v7.i1.9. World J Gastroenterol. 2001. PMID: 11819725 Free PMC article.
-
Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors.Drugs. 1992;44 Suppl 3:21-8. doi: 10.2165/00003495-199200443-00004. Drugs. 1992. PMID: 1280574 Review.
-
A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.Drug Saf. 1994 Dec;11(6):432-44. doi: 10.2165/00002018-199411060-00005. Drug Saf. 1994. PMID: 7727053 Review.